CNS Pharmaceuticals (CNSP) Net Cash Flow (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Net Cash Flow came in at -$2.6 million in Q4 2025, down 416.84% YoY from $834779.2 in Q4 2024, and down 16.73% on a QoQ basis from -$2.3 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Net Cash Flow (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Net Cash Flow data on file, last reported at -$2.6 million in Q4 2025.
- Quarterly Net Cash Flow fell 416.84% year-over-year to -$2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $757811.0 (down 87.18% YoY) and the FY2025 annual result came in at $739636.0, down 87.49% from the prior year.
- Net Cash Flow retreated to -$2.6 million in Q4 2025, from -$2.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $7.4 million in Q1 2022 to a low of -$4.9 million in Q1 2023.
- A 5-year average of -$341015.2 and a median of -$874499.5 in 2023 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 2371.33% in 2025, down 416.84% in 2025.
- Tracing CNSP's Net Cash Flow over 5 years: stood at -$3.3 million in 2021, then soared by 191.16% to $3.0 million in 2022, then plunged by 111.92% to -$360826.0 in 2023, then tumbled by 41.83% to -$511746.0 in 2024, then slumped by 416.84% to -$2.6 million in 2025.
- The last three Net Cash Flow figures came in at -$2.6 million (Q4 2025), -$2.3 million (Q3 2025), and -$917719.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 225.59 Mn |
| 10 | CNS Pharmaceuticals | 2.63 Mn | -4.57 Mn | - | -2.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.64 Mn |
| Dec 31, 2025 | -2.64 Mn |
| Sep 30, 2025 | -2.27 Mn |
| Sep 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -917,719.00 |
| Jun 30, 2025 | -917,719.00 |
| Mar 31, 2025 | 6.59 Mn |
| Mar 31, 2025 | 6.59 Mn |
| Dec 31, 2024 | -511,746.00 |
| Dec 31, 2024 | -511,746.00 |
| Sep 30, 2024 | 5.48 Mn |
| Sep 30, 2024 | 5.48 Mn |
| Jun 30, 2024 | 676,333.00 |
| Jun 30, 2024 | 676,333.00 |
| Mar 31, 2024 | 266,505.00 |
| Mar 31, 2024 | 266,505.00 |
| Dec 31, 2023 | -360,826.00 |
| Dec 31, 2023 | -360,826.00 |
| Sep 30, 2023 | -3.37 Mn |
| Sep 30, 2023 | -3.37 Mn |